- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22:30 | Medicenna launches public offering to fund clinical programs | 2 | Investing.com | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22:12 | Medicenna launches marketed public offering of securities | 1 | Seeking Alpha | ||
| 22:06 | Medicenna Therapeutics Corp.: Medicenna Announces the Launch of a Marketed Public Offering of Securities | 1 | GlobeNewswire (USA) | ||
| Di | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| Di | Medicenna Therapeutics Corp.: Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma | 96 | GlobeNewswire (Europe) | NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase... ► Artikel lesen | |
| 21.04. | Medicenna Therapeutics Corp: Medicenna releases MDNA113 preclinical data | 1 | Stockwatch | ||
| 21.04. | Medicenna Therapeutics Corp.: Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 09.04. | Medicenna Therapeutics Corp: Medicenna appoints Ibrahim as chief medical officer | 3 | Stockwatch | ||
| 18.03. | Medicenna Therapeutics Corp.: Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026 | 1 | GlobeNewswire (USA) | ||
| 13.02. | Medicenna Therapeutics Corp: Medicenna's Dec. 31 cash at $10.6 million | 1 | Stockwatch | ||
| 13.02. | Medicenna Therapeutics Corp: Medicenna appoints Sutin, Georgakis as directors | 1 | Stockwatch | ||
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update | 1.482 | GlobeNewswire (Europe) | Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated... ► Artikel lesen | |
| 13.02. | Medicenna Therapeutics Corp.: Medicenna Announces Changes to Board Composition | 1.324 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 15.01. | Medicenna Therapeutics Corp: Medicenna sets out plans, milestones for 2026 | 1 | Stockwatch | ||
| 15.01. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook | 1.037 | GlobeNewswire (Europe) | Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential... ► Artikel lesen | |
| 10.12.25 | Medicenna Therapeutics Corp.: Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors | 203 | GlobeNewswire (Europe) | MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case... ► Artikel lesen | |
| 23.10.25 | Medicenna Therapeutics Corp.: Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 | 328 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 25.09.25 | Medicenna Therapeutics Corp.: Medicenna Announces Results of Annual Meeting of Shareholders | 172 | GlobeNewswire (Europe) | TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... ► Artikel lesen | |
| 01.08.25 | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights | 235 | GlobeNewswire (Europe) | Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,350 | -1,56 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| EVOTEC | 4,540 | -10,63 % | Evotec-Aktie: Explodiert der Kurs jetzt Richtung 10€? | Nachdem der Kurs der Evotec-Aktie zuletzt deutlicher in Bewegung geraten ist, richtet sich der Blick nun auf die aktuellen Unternehmenszahlen und die operative Entwicklung. Der erwartungsgemäße Start... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,220 | +2,24 % | H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY) | ||
| TARSUS PHARMACEUTICALS | 64,66 | +8,07 % | Tarsus reiterates 2026 net product sales guidance of $670M-$700M as XDEMVY posts $145.4M in Q1 sales | ||
| BICARA THERAPEUTICS | 20,990 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,690 | +4,83 % | Arcutis Q1 2026: Umsatz steigt um 65 %, doch Expansionskosten führen zu höheren Verlusten | ||
| PRAXIS PRECISION MEDICINES | 346,46 | +0,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,330 | +1,30 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update | ||
| TANGO THERAPEUTICS | 25,510 | +8,55 % | Stifel Remains Bullish on Tango Therapeutics (TNGX) | ||
| C4 THERAPEUTICS | 3,660 | +15,46 % | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| BIONTECH | 78,95 | -1,07 % | Aktien im Fokus - LPKF Laser: Party bald vorbei? - BioNTech, BVB, Elmos, Rheinmetall und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 117,82 | +8,44 % | Inhibrx Biosciences, Inc.: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population... ► Artikel lesen | |
| BIOVENTUS | 10,400 | +2,56 % | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 26,850 | -8,24 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | - NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 - - Conference call today at 4:30 p.m. ET - RADNOR, Pa., May 06, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| ERASCA | 10,450 | +0,67 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.